TME Pharma NV (FRA:0N6A) Price-to-Tangible-Book : 4.45 (As of May. 20, 2025)

View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Price-to-Tangible-Book?

As of today (2025-05-20), TME Pharma NV's share price is €0.0756. TME Pharma NV's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was €0.02. Hence, TME Pharma NV's Price to Tangible Book Ratio of today is 4.45.

The historical rank and industry rank for TME Pharma NV's Price-to-Tangible-Book or its related term are showing as below:

FRA:0N6A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.37 Med: 3.86 Max: 4.41
Current: 3.78

During the past 11 years, TME Pharma NV's highest Price to Tangible Book Ratio was 4.41. The lowest was 3.37. And the median was 3.86.

FRA:0N6A's Price-to-Tangible-Book is ranked worse than
60.05% of 1199 companies
in the Biotechnology industry
Industry Median: 2.66 vs FRA:0N6A: 3.78

A closely related ratio is called PB Ratio. As of today, TME Pharma NV's share price is €0.0756. TME Pharma NV's Book Value per Sharefor the quarter that ended in Dec. 2024 was €0.02. Hence, TME Pharma NV's P/B Ratio of today is 4.45.

TME Pharma NV Price-to-Tangible-Book Historical Data

The historical data trend for TME Pharma NV's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Price-to-Tangible-Book Chart

TME Pharma NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.87

3.48

4.04

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	4.02	4.04

Competitive Comparison of TME Pharma NV's Price-to-Tangible-Book

For the Biotechnology subindustry, TME Pharma NV's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

TME Pharma NV Price-to-Tangible-Book Calculation

TME Pharma NV's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	0.0756	/	0.017
	=	4.45

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

TME Pharma NV Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ALTME:France

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines